LGM Pharma Acquires Nexgen Pharma's Drug Product CDMO Business

July 23, 2020

LGM Pharma has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, expanding LGM's CDMO capabilities and U.S.-based manufacturing footprint. Financial support for the transaction was provided by private equity firm New Harbor Capital; Nexgen Pharma sold its pharmaceutical CDMO unit to allow the company to focus on other healthcare segments.

Buyers
LGM Pharma, New Harbor Capital
Targets
Nexgen Pharma (formulation development and drug product contract manufacturing business)
Sellers
Nexgen Pharma
Industry
Pharmaceuticals
Location
California, United States
Transaction Type
Divestiture

Explore More

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.